Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.

Mednet Member

Radiation Oncology · Memorial Sloan-Kettering Cancer Center

A few points to consider about this modern perspective on adjuvant CXRT for pancreatic cancer are: A positive margin is one of the least controversial indications for adjuvant CXRT in pancreatic cancer. If you get a case to treat, you don't want dose to be the reason for failure. 50.4 Gy has been th...